Translational cellular models, primary mammalian cultures, Franz diffusion cell permeation, cytotoxicity assays, and gene expression analysis replacing animal models where applicable.
Translational drug absorption and metabolic stability in isolated viable tissue preparations.
Ex-vivo organotypic slice cultures maintaining physiological cell-cell interactions.
Franz diffusion cell skin permeation profiling for transdermal patches and topical formulations.
Bovine/porcine isolated corneal tissue diffusion assays for ophthalmic drug delivery systems.
Isometric organ bath contraction/relaxation pharmacology (ileum, aorta, trachea, atrium).
Ex-vivo tissue integration and local inflammatory response to implantable biomaterials.
Histopathological and biochemical toxicity profiling in excised target organs.
Ex-vivo target receptor binding, enzyme inhibition, and biomarker response monitoring.
Maintenance and expansion of primary human/rodent cells and immortalized cell lines (HeLa, Caco-2, HEK293, NIH3T3).
Mesenchymal stem cell (MSC) expansion, differentiation assays, and stem cell toxicity screening.
Anticancer efficacy screening across tumor cell lines (MCF-7, A549, HT-29, PC-3).
MTT, XTT, CCK-8, Trypan blue, and ATP bioluminescence proliferation measurements.
LDH release, Annexin V / PI flow cytometry, Caspase 3/7 activation, and DNA laddering.
Scratch wound healing assays and Transwell Matrigel invasion assays for metastatic screening.
High-content fluorescent microscopy, live cell imaging, DAPI/FITC staining, and immunofluorescence.
RT-qPCR mRNA expression analysis and Western Blotting / ELISA protein quantification.
96/384-well microplate compound screening, IC50 determination, and dose-response curve fitting.
